Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
Date:2/20/2008

- Q4 2007 net revenues grew 29.8%, as compared to Q4 2006, to RMB45.7

million (US$6.3 million)

- Q4 2007 net income grew 152.2%, as compared to Q4 2006, to RMB17.9

million (US$2.5 million) - 2007 fiscal year net revenues increased 41.0% year-over-year to RMB180.2

million (US$24.7 million) - 2007 fiscal year net income grew 167.4% year-over-year to RMB81.5 million

(US$11.2 million)

SHENYANG, China, Feb. 20 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) (''3SBio'' or ''the Company''), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2007.

Fourth Quarter 2007 Financial Highlights:

-- Total net revenues increased 29.8% over the fourth quarter 2006 to

RMB45.7 million (US$6.3 million).

-- Net revenue from our flagship injectable recombinant human

erythropoietin products, or EPO products, marketed under our EPIAO

brand, increased 14.7% over the fourth quarter 2006 to RMB29.8 million

(US$4.1 million).

-- Net revenue from our protein-based therapeutic recombinant human

thrombopoietin products, or TPO products, marketed under our TPIAO

brand, increased 99.3% over the fourth quarter 2006 to RMB11.7 million

(US$1.6 million).

-- Operating income decreased 29.6% compared to the fourth quarter 2006

to RMB6.1 million (US$0.8 million)

-- Net income increased 152.2% over the fourth quarter 2006 to RMB17.9

mi
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. 3SBio Inc. Announces Change to the Board of Directors
2. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
3. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
5. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
6. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
9. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
10. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
11. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... (PRWEB) November 23, 2014 Apiscent ... supplier of fine chemical ingredients to the global ... launch of its new website, Apiscent.com. , The ... Apiscent Labs, clean design, easy navigation, rotating images ... Apiscent Labs stand out. , The ...
(Date:11/22/2014)... 21, 2014 RURO, Inc., a ... has released Limfinity® version 5.1.4. , RURO’s deployment ... Limfinity® than ever in RURO’s 8 year history. ... framework enhancement. Limfinity® version 5.1.4 is the perfect ... beyond bug fixes! , Limfinity® 5.1.4 release highlights ...
(Date:11/22/2014)... November 21, 2014   ... Chief Commercial Officer zu KLOX    ... und Chief Financial Officer bestellt    ... Vermarktung seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen ... das "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 Author Matthew ... Walk to the Other Side” published as a ... Finalist in the “Fiction: Short Story” category of the ... Keen, President and CEO of USA Book News, said ... and independent publishers, including Simon & Schuster, Penguin, John ...
Breaking Biology Technology:RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... MA - In work that could jumpstart the promising field ... body to treat a variety of diseases and tissue defects, ... that could solve one of the key challenges associated with ... transplantation. In the work, reported in the journal ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... has published results from the North American Phase 3 trial ... fidaxomicin as a treatment for patients with Clostridium difficile ... significantly reduced recurrence rates and increased global cure rates when ...
... ST. LOUIS, Feb. 2, 2011 Sigma Life Science, the ... SIAL ), today announced that its SAGE Labs initiative ... genomes for six of the most widely used strains of ... generate and analyze sequence data using next generation sequencing systems, ...
Cached Biology Technology:Engineered cells could usher in programmable cell therapies 2Engineered cells could usher in programmable cell therapies 3The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 2The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 3The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 4The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 5The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 6Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 2Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 3Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 4
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
(Date:11/7/2014)... 6, 2014 Leading Biometric companies aim ... security revolutionizing online transactions.  Companies in focus today are: NXT-ID, ... BABA ), Google Inc. (NASDAQ: GOOG ... (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: MA) ... NXTDW), a biometric authentication company focused on the growing mobile ...
(Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3
... A tiny, fast switch that uses water droplets to create ... mechanism found in palm beetles. , The new beetle-inspired ... on the scale of a micron -- a millionth of ... larger applications like powerful adhesive bonding. Like the transistor, whose ...
... that the brains of alcoholics are smaller, lighter ... speakers at the October 2004 Congress for the ... Mannheim, Germany reviewed what is known about the ... shrinkage. Proceedings are published in the June issue ...
... and Infectious Diseases (NIAID), part of the National Institutes ... which cause such serious diseases as West Nile fever, ... defenses in different ways depending on whether they are ... to new approaches to developing vaccines and treatments against ...
Cached Biology News:Beetle-inspired switch uses water for bonding 2Investigating 'brain shrinkage' in alcoholics 2Investigating 'brain shrinkage' in alcoholics 3Investigating 'brain shrinkage' in alcoholics 4Investigating 'brain shrinkage' in alcoholics 5Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 2Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 3
DNA fragmentation factor & Inhibitor of CAD...
Component in MasterPure™ Purification Kits...
Anti-gp340 Monoclonal Antibody Description: 100 g Research Focus: cancer & cell proliferation Storage: -20C Shipping Temperature: 4C...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Biology Products: